MLYS 250516 20.00C(MLYS250516C20000) Stock Price Today

US OptionsDetailed Quotes

MLYS250516C20000

Watchlist

0.73
0.000.00%

15min DelayTrading Apr 16 15:34 ET

0.00High0.00Low

Intraday

5D
Daily

News

Mineralys Therapeutics(MLYS.US) 10% Shareholder Buys US$3.5 Million in Common Stock
Moomoo NewsApr 25 19:03 ET
Mineralys Therapeutics' Lorundrostat Shows Efficacy in NEJM-published Study
TipRanksApr 23 17:30 ET
Express News | Mineralys Therapeutics Reveals Publication Of Pivotal Phase 2 Advance-HTN Results In The New England Journal Of Medicine
BenzingaApr 23 17:26 ET
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
GlobeNewswireApr 23 17:23 ET
Institutional Investors Must Be Pleased After a 8.1% Gain Last Week That Adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) One-year Returns
Yahoo FinanceApr 12 08:38 ET
New Analyst Forecast: $MLYS Given 'Buy' Rating
Quiver QuantitativeApr 7 12:28 ET

Comments

Teddy123

Apr 24 11:04

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

$Mineralys Therapeutics (MLYS.US)$
Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial

Teddy123

Mar 31 10:04

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual

$Mineralys Therapeutics (MLYS.US)$
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial

Teddy123

Mar 30 21:51

$Mineralys Therapeutics (MLYS.US)$
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial

Centerpoint

Mar 10 23:12

$Mineralys Therapeutics (MLYS.US)$ need 5mil more volume and this would really get moving ...

Jaguar8

Mar 10 21:58

NEWS

$Mineralys Therapeutics (MLYS.US)$
03/10/2025 - 04:00 AM
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 –
– Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) asse...